Cargando…
Psychometric evaluation of a visual analog scale for the assessment of anxiety
BACKGROUND: Fast-acting medications for the management of anxiety are important to patients and society. Measuring early onset, however, requires a sensitive and clinically responsive tool. This study evaluates the psychometric properties of a patient-reported Global Anxiety - Visual Analog Scale (G...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904728/ https://www.ncbi.nlm.nih.gov/pubmed/20529361 http://dx.doi.org/10.1186/1477-7525-8-57 |
_version_ | 1782183900043280384 |
---|---|
author | Williams, Valerie SL Morlock, Robert J Feltner, Douglas |
author_facet | Williams, Valerie SL Morlock, Robert J Feltner, Douglas |
author_sort | Williams, Valerie SL |
collection | PubMed |
description | BACKGROUND: Fast-acting medications for the management of anxiety are important to patients and society. Measuring early onset, however, requires a sensitive and clinically responsive tool. This study evaluates the psychometric properties of a patient-reported Global Anxiety - Visual Analog Scale (GA-VAS). METHODS: Data from a double-blind, randomized, placebo-controlled study of lorazepam and paroxetine in patients with Generalized Anxiety Disorder were analyzed to assess the reliability, validity, responsiveness, and utility of the GA-VAS. The GA-VAS was completed at clinic visits and at home during the first week of treatment. Targeted psychometric analyses—test-retest reliabilities, validity correlations, responsiveness statistics, and minimum important differences—were conducted. RESULTS: The GA-VAS correlates well with other anxiety measures, at Week 4, r = 0.60 (p < 0.0001) with the Hamilton Rating Scale for Anxiety and r = 0.74 (p < 0.0001) with the Hospital Anxiety and Depression Scale - Anxiety subscale. In terms of convergent and divergent validity, the GA-VAS correlated -0.54 (p < 0.0001), -0.48 (p < 0.0001), and -0.68 (p < 0.0001) with the SF-36 Emotional Role, Social Function, and Mental Health subscales, respectively, but correlated much lower with the SF-36 physical functioning subscales. Preliminary minimum important difference estimates cluster between 10 and 15 mm. CONCLUSIONS: The GA-VAS is capable of validly and effectively capturing a reduction in anxiety as quickly as 24 hours post-dose. |
format | Text |
id | pubmed-2904728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29047282010-07-16 Psychometric evaluation of a visual analog scale for the assessment of anxiety Williams, Valerie SL Morlock, Robert J Feltner, Douglas Health Qual Life Outcomes Research BACKGROUND: Fast-acting medications for the management of anxiety are important to patients and society. Measuring early onset, however, requires a sensitive and clinically responsive tool. This study evaluates the psychometric properties of a patient-reported Global Anxiety - Visual Analog Scale (GA-VAS). METHODS: Data from a double-blind, randomized, placebo-controlled study of lorazepam and paroxetine in patients with Generalized Anxiety Disorder were analyzed to assess the reliability, validity, responsiveness, and utility of the GA-VAS. The GA-VAS was completed at clinic visits and at home during the first week of treatment. Targeted psychometric analyses—test-retest reliabilities, validity correlations, responsiveness statistics, and minimum important differences—were conducted. RESULTS: The GA-VAS correlates well with other anxiety measures, at Week 4, r = 0.60 (p < 0.0001) with the Hamilton Rating Scale for Anxiety and r = 0.74 (p < 0.0001) with the Hospital Anxiety and Depression Scale - Anxiety subscale. In terms of convergent and divergent validity, the GA-VAS correlated -0.54 (p < 0.0001), -0.48 (p < 0.0001), and -0.68 (p < 0.0001) with the SF-36 Emotional Role, Social Function, and Mental Health subscales, respectively, but correlated much lower with the SF-36 physical functioning subscales. Preliminary minimum important difference estimates cluster between 10 and 15 mm. CONCLUSIONS: The GA-VAS is capable of validly and effectively capturing a reduction in anxiety as quickly as 24 hours post-dose. BioMed Central 2010-06-08 /pmc/articles/PMC2904728/ /pubmed/20529361 http://dx.doi.org/10.1186/1477-7525-8-57 Text en Copyright ©2010 Williams et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Williams, Valerie SL Morlock, Robert J Feltner, Douglas Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title | Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title_full | Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title_fullStr | Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title_full_unstemmed | Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title_short | Psychometric evaluation of a visual analog scale for the assessment of anxiety |
title_sort | psychometric evaluation of a visual analog scale for the assessment of anxiety |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904728/ https://www.ncbi.nlm.nih.gov/pubmed/20529361 http://dx.doi.org/10.1186/1477-7525-8-57 |
work_keys_str_mv | AT williamsvaleriesl psychometricevaluationofavisualanalogscalefortheassessmentofanxiety AT morlockrobertj psychometricevaluationofavisualanalogscalefortheassessmentofanxiety AT feltnerdouglas psychometricevaluationofavisualanalogscalefortheassessmentofanxiety |